By: Sara Riascos  Mar. 14, 2022

Chronic Obstructive Pulmonary Disease (COPD) is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing.Ventolin (Albuterol) is an Inhaled beta-2-agonist. Studies have shown the use of Ventolin (Albuterol) had an improvement in Chronic Obstructive Pulmonary Disease (COPD) compared to the baseline. Other studies have shown the use of Ventolin (Albuterol) is safe for patients older than 4.

By: Sara Riascos  Mar. 03, 2022

Heart Failure is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Furosemide is a loop diuretic medication used to treat fluid build-up due to heart failure, liver scarring, or kidney disease. Studies have shown that the early use of Furosemide was associated with lower mortality for heart Failure Patients.

Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of Furosemide within 7 days of hospitalization was associated with lower hospital readmission rates for Heart Failure Patients at Florida Hospital in Orlando, Florida. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

By: Sara Riascos  Mar. 03, 2022

Major Joint Replacement is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. XARELTO(Rivaroxaban) is a factor XA inhibitor prescribed by doctors to prevent blood clots from irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. Studies have shown that the early use of XARELTO(Rivaroxaban) after a Major joint replacement surgery is associated with decreased the rate of symptomatic VTE. Other studies have shown that XARELTO(Rivaroxaban) had a superior effect in THA patients. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of XARELTO(Rivaroxaban) within 7 days of hospitalization was associated with lower hospital readmission rates for Major Joint Replacement at Bethesda Hospital at Boynton Beach, Florida. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

By: Sara Riascos  Feb. 28, 2022

Major Joint Replacement is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. XARELTO(Rivaroxaban) is a factor XA inhibitor prescribed by doctors to prevent blood clots from irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. Studies have shown that the early use of XARELTO(Rivaroxaban) after a Major joint replacement surgery is associated with decreased the rate of symptomatic VTE. Other studies have shown that XARELTO(Rivaroxaban) had a superior effect in THA patients. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of XARELTO(Rivaroxaban) within 7 days of hospitalization was associated with lower hospital readmission rates for Major Joint Replacement at Quail Creek Surgical Hospital, in AMARILLO, TX, 79124. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

By: Sara Riascos  Feb. 28, 2022

Major Joint Replacement is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Eliquis(Apixaban) is an anticoagulant prescribed by doctors to reduce the risk of stroke caused by blood clots. Studies have shown that the early use of Eliquis (Apixaban) after a Major joint replacement surgery is associated with lower rates of clinically relevant bleeding. Other studies have shown that Eliquis reduces the risk of blood clots forming in lungs and legs after undergoing a Major Joint Replacement surgery. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of Eliquis(Apixaban) within 7 days of hospitalization was associated with lower hospital readmission rates for Major Joint Replacement at Ascension St. John Broken Arrow. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

Frailty is a condition marked by signs of declining vitality and health outcomes such as fatigue, weakness, poor physical activity, slow walking speed, and weight loss. According to several studies, frailty is common among older adults and approximately 10% of individuals, 65 years or older, are frail. Frailty is associated with an increase in rehospitalization, in-hospital mortality, longer length of stay, and higher hospitalization costs. This can adversely impact quality programs such as Value-Based Purchasing (VBP), Hospital Readmissions Reduction Program (HRRP), Bundled Payments for Care Improvement - Advanced (BPCI-A), and CMS Star Rating.

By: Sampath  Jan. 24, 2022

Diabetes & Chronic Kidney Disease Risk Factors are associated with higher Heart Failure Readmission & Mortality based on Real World Evidence at Piedmont Fayette Hospital

Dexur’s analysis of medicare claims of hospitals within a 10-mile radius of New York City, NY, showed that Hospital for Special Surgery, Lenox Hill Hospital, and NewYork-Presbyterian/Weill Cornell Medical Center were the most cost-efficient hospitals over a 90 day episode for Spine Surgeries. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. Total cost of care data helps patients make appropriate choices and helps local ACOs, such as NewYork Quality Care, FamilyHealth ACO, LLC, Alliance for Integrated Care of New York, LLC, and HHC ACO, make appropriate referral choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 460: Spinal Fusion Except Cervical without Major Complication or Comorbidity, to adjust for complications and comorbidities.

By: Sharath Joji  Jul. 19, 2021

By: Sharath Joji  Jul. 16, 2021